"And then in the biosimilars, we stick essentially with what we've said before, which is, we would expect the first biosimilars with Herceptin and MabThera outside the United States in 2016. Of course, that means that we would need to see a filing -- I'm sorry, in Herceptin in 2015 and in MabThera it's 2016, but we would need to see a filing soon in Europe to see Herceptin in 2000 -- no, excuse me, 2016 for both. I'm just getting my years mixed up. So we will need to see a filing too for 1 or 2 of those products towards the end of this year for them to enter into the market in early 2016."
From seekingalpha.com Roche transcript.
News 
Market Data 
Discover 
